NCT07083388View on ClinicalTrials.gov

"A Study to Evaluate the Pharmacokinetics and Safety Between BR3006 and Co-administration of BR3006A, BR3006B, and BR3006C in Healthy Adult Volunteers (Fasting)"

PHASE1RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 3, 2025

Primary Completion Date

July 3, 2026

Study Completion Date

July 3, 2026

Conditions
Diabetes Mellitus
Interventions
DRUG

Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg

Orally administered once per day

DRUG

Dapagliflozin 10 mg

Orally administered once per day

DRUG

Pioglitazone 30 mg

Orally administered once per day

DRUG

Metformin HCl 1000 mg

Orally administered once per day

Trial Locations (1)

08779

RECRUITING

H Plus Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY